BioStock: Positive phase II results for Curasight in neuroendocrine cancer

Positive phase II study results keep on trickling in for Danish Curasight, strengthening its uPAR approach to diagnostics and cancer treatment. Latest in a string of news for the company when positive results regarding neuroendocrine cancer were announced and published in the Journal of Nuclear Medicine.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/02/positive-phase-ii-results-for-curasight-in-neuroendocrine-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se